

***WHO Guideline Development Group:******WHO Guideline on balanced national policies for ensuring access to and safe use of controlled medicines***

Geneva, Switzerland

**Disclaimer:**

In order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with WHO meetings and activities involving the provision of technical/normative advice, the names and brief biographies of individuals (“Published Information”) being considered for participation in a WHO-convened Guideline Development Group are disclosed for public notice and comment.

The Published Information is provided by the experts themselves and is the sole responsibility of the individuals concerned. WHO is not responsible for the accuracy, veracity and completeness of the Published Information provided. Furthermore, in no event will WHO be responsible or liable for damages in relation to the use of, and reliance upon, the Published Information.

The comments received by WHO through the public notice and comment process are treated confidentially and their receipt will be acknowledged through a generic email notification to the sender. Comments brought to the attention of WHO through this process are an integral component of WHO’s conflict of interest assessment process and are carefully reviewed. WHO reserves the right to discuss information received through this process with the relevant expert and disclose to this expert the name and affiliation of the provider of such information. Upon review and assessment of the information received through this process, WHO, in its sole discretion, may take appropriate management action in accordance with its policies.

Guideline Development Groups provide technical and/or normative advice and recommendations to WHO. Participation in a Guideline Development Group convened by WHO does not necessarily mean that the views expressed by the expert concerned are shared by WHO and/or represent the decisions or stated policy of WHO.

The list of participating experts, a summary of relevant interests disclosed by such experts, and any appropriate mitigation measures taken by WHO relating to the management of conflicts of interests, will be reported publicly in accordance with WHO policies.

Please send any comments to **[controlled.medicines@who.int](mailto:controlled.medicines@who.int)** by **9<sup>th</sup> February 2020**

**Surname, first name(s) and initial** Al-Shahri, Mohammad Zafir

**Institutional affiliation(s)** King Faisal Specialist Hospital and Research Center

**Academic degrees** MBChB, ABFM, FFCM, ABHPM

**City and country of primary residence** Riyadh, Saudi Arabia

Professor Mohammad Z. Al-Shahri is a graduate of King Abdulaziz University, Jeddah. He trained in Family and Community Medicine at King Faisal University (KFU) and then subspecialized in Palliative Medicine. His subspecialty certification includes a fellowship from King Faisal Specialist Hospital and Research Center, Riyadh (KFSHRC-R); a fellowship from the University of Alberta, Canada; and the American Board of Hospice and Palliative Medicine.

Professor Al-Shahri was the first sub-specialized palliative care physician in Saudi Arabia and the Arab World and has been practicing Palliative Medicine since 2000. In addition to his clinical appointment as a consultant, he is the Head of Palliative Care Medicine and also the Program Director of the Palliative Medicine Fellowship Program at KFSHRC-R. He also holds an adjunct academic post at Alfaisal University as a Professor of Palliative Medicine.

Professor Al-Shahri is the founding President of the Saudi Society of Palliative Care and the Arab Group for Palliative Medicine. He authored the first book on palliative care in Arabic language and has tens of scientific contributions published in regional and international peer-reviewed journals.

**Surname, first name(s) and initial** Bero, Lisa

**Institutional affiliation(s)** University of Sydney

**Academic degrees** BSc, PhD

**City and country of primary residence** Sydney, Australia

Lisa A. Bero, PhD directs the Evidence, Policy and Influence Collaborative Research Program at the Charles Perkins Centre, with Research nodes in Bias, Evidence Synthesis and Pharmaceutical Policy. Professor Bero is Chair of Medicines Use and Health Outcomes, Faculty of Medicine and Health, School of Pharmacy, The University of Sydney. She was Co-Chair, Cochrane Governing Board from 2014-2018 and is currently Senior Editor, Cochrane Public Health and Health Systems Network. She has developed and validated methods for assessing bias in the design, conduct and dissemination of research on pharmaceuticals, tobacco, chemicals, and complex public health interventions. Prof. Bero has also conducted analyses to examine the dissemination and policy implications of research evidence. Her international activities include member and chair of the World Health Organization (WHO) Expert Committee on the Selection and Use of Essential Medicines. Prof. Bero serves on several national and international committees related to conflicts of interest, evidence and decisions.

**Surname, first name(s) and initial:** Broers, Barbara

**Institutional affiliation(s)** Geneva Universities Hospital

**Academic degrees** Master in Medicine, Masters in Epidemiology and Biostatistics, Professor in Addiction Medicine

**City and country of primary residence** Geneva, Switzerland

Graduate from the Medical Faculty of the University of Amsterdam, NL (1987); Master's Degree in Epidemiology and Biostatistics, McGill University, Montreal; Swiss specialization title in Prevention and Public Health. Over 25 years of clinical, teaching and research experience at the Geneva University Hospitals in the field of substance use, addiction, HIV and harm reduction. Two years' NGO experience in developing countries (women's health and teaching). In charge of the module "gender and health" of the Diploma on Gender, University of Geneva (2002-2006). Vice-president of the Swiss Society of Addiction Medicine. Member of the Education Committee of the International Society for Addiction Medicine. Vice-president of the Swiss Federal Commission on Addiction-related Questions. Member of the Swiss Federal Expert Group on Medical Cannabinoids. Co-producer of a MOOC "drugs, drug use, drug policy and health".

**Surname, first name(s) and initial:** Buitrago, Rosa

**Institutional affiliation(s)** School of Pharmacy - Universidad de Panamá

**Academic degrees** Master in Clinical Pharmacy, Bachelor of Science

**City and country of primary residence** Panama, Panama

Rosa Buitrago is Professor of Pharmacology and cancer pain management with expertise in access to controlled medicines. She has been working during the last 18 years improving access to controlled medicines not only in Panama but also in Central America and other countries in Latin America region. She was part of the first cohort of IPPSG from University of Wisconsin and served to the WHO Expert Committee on Drug Dependence. She has been peer reviewer of different WHO documents related to this update and have been using the two main documents prepared by WHO in helping countries to increase access to controlled medicines. She has introduced relevant graduate programs to prepare health care professionals in access to controlled medicines, pain management and palliative care. She recently collaborated with UNODC in a consultancy on "Access to controlled medicines in Panama".

**Surname, first name(s) and initial** Burke-Shyne, Naomi

**Institutional affiliation(s)** Harm Reduction International

**Academic degrees:** Bachelor of Laws, Masters of International and Community Development

**City and country of primary residence** London, UK

Naomi is the Executive Director of Harm Reduction International where she supports policy, advocacy and technical assistance work at the intersection of harm reduction and human rights, including mapping and analysis on opioid agonist treatment for people who use drugs. From 2014-2017, Naomi worked for the Open Society Foundations' Public Health Program, leading a portfolio of funding and policy engagement that supported civil society to challenge the negative impact of drug policy on access to controlled medicines, and strengthen access to justice for people who use drugs.

Naomi worked for the International Development Law Organization's HIV and Health Law program between 2009 and 2014, focusing on access to justice and the rights of groups vulnerable to HIV. Naomi started her career as a lawyer, and has a Bachelor of Laws and a Masters in International and Community Development.

**Surname, first name(s) and initial** Downing, Julia

**Institutional affiliation(s)** International Children's Palliative Care Network (UK), Makerere University (Uganda)

**Academic degrees** Bachelor of Nursing, Masters in Medical Science, PhD

**City and country of primary residence** London, UK and Kampala, Uganda

Professor Downing is an experienced palliative care nurse, educationalist and researcher. She is a Professor in Palliative Care at Makerere University, Uganda and the Chief Executive of the International Children's Palliative Care Network (ICPCN). She has extensive experience in pain assessment and management, education, research, presenting at conferences and writing for publication. She has been working within palliative care for 29 years, with nineteen of those working internationally in Uganda, Africa, Eastern Europe and globally developing palliative care services for adults and children. She is recognised as a global expert in children's palliative care.

**Surname, first name(s) and initial** Gyansa-Lutterodt, Martha

**Institutional affiliation(s)** Ministry of Health Ghana

**Academic degrees:** Doctor of Pharmacy, MA, BPharm

**City and country of primary residence:** Tema, Ghana

Dr. (Mrs.) Martha Gyansa-Lutterodt is the Director of Technical Coordination at the Ministry of Health Ghana. Martha is a product of KNUST Ghana, Leeds University, United Kingdom in Health Policy and GIMPA's School of Governance and Leadership for Leadership and Governance. Martha also holds a Doctorate in Pharmacy from KNUST, Ghana. She serves on several national and international boards and also was a Lancet Commissioner on Essential Medicines in 2015. She is an Expert member of the World Health Organisation Expert Committee on Medicines Policy and Management. She has several publications on various topics like Universal Health Coverage, TRIPS, DOHA and Access to medicines, policy options for Ghana, Antibiotic Resistance in Ghana by Lancet Infectious Diseases among others. Martha is a fellow of West African Post Graduate College of Pharmacists and Foundation fellow of Ghana College of Pharmacists. She is the chair for Ghana's Alliance for Antimicrobial Resistance. She was an Expert member of United Nations Interagency Coordinating Group on Antimicrobial Resistance. Martha is a board member/Secretary of Africa Palliative Care Association. Until March 2019 Martha was the immediate Chief Pharmacist and Director of Pharmaceutical Services for Ghana.

**Surname, first name(s) and initial** Humphreys, Keith

**Institutional affiliation(s)** Stanford University / Veterans Health Administration

**Academic degrees** BA, A.M., Ph.D.

**City and country of primary residence** Stanford, USA

Keith Humphreys is a Professor and the Section Director for Mental Health Policy in the Department of Psychiatry and Behavioral Sciences at Stanford University. He is also a Senior Research Career Scientist at the VA Health Services Research Center in Palo Alto and an Honorary Professor of Psychiatry at the Institute of Psychiatry, King's College, London. His research addresses the prevention and treatment of addictive disorders, the formation of public policy and the extent to which subjects in medical research differ from patients seen in everyday clinical practice.

For his work in the multinational humanitarian effort to rebuild the psychiatric care system of Iraq and in the national redesign of the VA health system's mental health services for Iraq war veterans, he won the 2009 American Psychological Association Award for Distinguished Contribution to the Public Interest. He and the authors of "Drug Policy and the Public Good" won the 2010 British Medical Association's Award for Public Health Book of the Year.

Dr. Humphreys has been extensively involved in the formation of public policy, having served as a member of the White House Commission on Drug Free Communities, the VA National Mental Health Task Force, and the National Advisory Council of the U.S. Substance Abuse and Mental Health Services Administration. During the Obama Administration, he spent a sabbatical year as Senior Policy Advisor at the White House Office of National Drug Control Policy. He has also testified on numerous occasions in Parliament and advises multiple government agencies in the U.K.

**Surname, first name(s) and initial** Kaduri, Pamela

**Institutional affiliation(s)** University of Toronto / Muhimbili University of Health and Allied Sciences

**Academic degrees:** MD, MMed (Psychiatry), MscCH

**City and country of primary residence:** Toronto, Canada

Dr. Pamela Kaduri (MD, Mmed, MscCH) is an Assistant Professor at the Department of Psychiatry, University of Toronto and a staff Psychiatrist at the Centre for Addiction and Mental Health. She is also an adjunct faculty with the Muhimbili University of Health and Allied Sciences (MUHAS), Tanzania. Dr. Kaduri completed her clinical and research fellowships in Addiction Psychiatry and the Social Aetiology of Mental illness with the Department of Psychiatry at the University of Toronto (UoT) and the Center for Addiction and Mental Health (CAMH), Canada. She received her MD degree at MUCHS, University of Dar es salaam, Tanzania and obtained her Masters of Medicine in Psychiatry in Tanzania, and a Master of Science in Community Health focusing in Mental Health and Addictions at UoT.

Dr. Kaduri's experience encompasses teaching, research, policy and clinical care provision in mental health and addictions. She has worked in areas of injection drug use and HIV, drug dependence treatment, opioids, tobacco and alcohol interventions as well as improving access to mental health care services. She has a number of peer reviewed publications on substance use and has played a crucial role in the development and implementation of methadone assisted treatment programs in Africa. Dr. Kaduri is also a member of various local and international professional bodies and served as an advisory member in several committees in Africa.

**Surname, first name(s) and initial** Krakauer, Eric

**Institutional affiliation(s)** Harvard Medical School

**Academic degrees:** MD, PhD

**City and country of primary residence:** Newton, USA

Eric L. Krakauer, MD, PhD, is Associate Professor of Medicine and of Global Health & Social Medicine at Harvard Medical School and a practicing palliative medicine specialist at Massachusetts General Hospital where he also directs the Global Palliative Care Program. In 2016-2017, he served as Medical Officer for Palliative Care at WHO headquarters in Switzerland. In this capacity, he edited WHO manuals on integrating palliative care into primary health care, into pediatrics, and into responses to humanitarian crises. He also has served on the Lancet Commission on Global Access to Palliative Care, as a visiting medical staff member of the Kigali University Teaching Hospital (CHUK) in Rwanda, and as Honorary Chair of the Department of Palliative Care at the University of Medicine & Pharmacy at Ho Chi Minh City, Vietnam.

**Surname, first name(s) and initial** Rahimi-Movaghar, Afarin

**Institutional affiliation(s)** Iranian National Center for Addiction Studies, Tehran University of Medical Sciences

**Academic degrees:** MD, MPH

**City and country of primary residence** Tehran, Iran

Afarin Rahimi-Movaghar, MD, MPH, Professor of Psychiatry, Director, Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran

Afarin Rahimi-Movaghar has more than 20 years of experience in policy-making and research in the fields of substance use and mental health. She has served in several national level positions, including as the director of the offices on mental health and substance use services in the Iranian Ministry of Health, as well as director of the national mental health research department.

Her research experiences include directing several national surveys –including Iranian national substance use survey, systematic reviews, and qualitative studies. Dr. Rahimi's main interests are in the fields of public health and epidemiology. She has numerous publications in these fields. She has been a member or principal investigator for developing several national or global evidence-based guidelines on substance dependence.

Dr. Rahimi has done three reviews on substance use situation and interventions in the Middle East and North Africa in the years 2002, 2008, 2012 and 2016. She has been a consultant for several programs for MENA region countries and member of several advisory committees for the WHO headquarter and United Nations Office for Drugs and Crime (UNODC). She has been a member of Advisory Group on Development of ICD-11 and a member WHO Expert Committee on Drug Dependence (ECDD).

At the time being, Afarin Rahimi-Movaghar is the head of the Iranian National Center for Addiction Studies (INCAS), and the head of national guideline development group on addiction.



**Surname, first name(s) and initial** Rajagopal, MR

**Institutional affiliation(s)** Pallium India, WHO Collaborating Centre for Policy and Training on Access to Pain Relief

**Academic degrees** BSc, MBBS, MD, MNAMS

**City and country of primary residence** Thiruvananthapuram, India

A person's right to be treated, not merely as a unidimensional patient suffering with a life-altering disease, but as a human being with multiple dimensions that determine his or her quality of life, lies at the heart of Dr Rajagopal's work on Palliative Care. His work spans three decades and more.

Dr Rajagopal is the director of the WHO Collaborating Center for Policy and Training on Access to Pain Relief at Trivandrum Institute of Palliative Sciences (TIPS) and the founder-chairman of Pallium India.

Finding that over a 15-year period, only 17 of India's 28 states had adopted the simplified rules, his colleagues and he pushed for changing the Narcotic Drugs and Psychotropic Substances (NDPS) Act of India of 1985. In February 2014, the Indian Parliament passed the Narcotics Amendment Act which is now getting implemented in different states across the country. His initiative has also contributed to the development of a Government policy on Palliative Care in the state of Kerala in 2008 and Government of India's National Palliative Care Strategy in 2012.

Dr. Rajagopal is a Commissioner of the Lancet commission on global access to palliative care and pain relief.

Dr Rajagopal won the 'Alison Des Forges award for extraordinary activism' from Human Rights Watch in 2014, the award for excellence in pain management from the International Association for Study of Pain (IASP) in 2009 and the Marie Nyswander award of 2009. A documentary film on Dr. Rajagopal's contributions to palliative care in India titled "Hippocratic: 18 experiments in gently shaking the world" produced by Moonshine Agency, Australia, was released on October 14, 2017. In 2017, Dr. Rajagopal was named one of the 30 most influential leaders in hospice and palliative medicine by American Academy of Hospice and Palliative Medicine (AAHPM).

In recognition of the yeomen service to the field of palliative medicine, Dr Rajagopal was awarded a Padma Shree in 2018.

**Surname, first name(s) and initial** Sebisubi, Fred

**Institutional affiliation(s)** Ministry of Health

**Academic degrees:** BSc, MSc.Pharmacy, PhD

**City and country of primary residence** Kampala, Uganda

Dr. Sebisubi is currently Assistant Commissioner Quality Assurance in the Department of Pharmacy and Natural Medicines at the Ministry of Health, Uganda. Prior to the current position, he worked as Senior and Principal Pharmacist in the same Ministry. Over the years, he has actively participated in policy, guidelines development and review including for Palliative Care, resource mobilization, coordination of departments and stake holders, monitoring and evaluation of the pharmaceutical service delivery in the country. He has been very instrumental in scale up of palliative care in Uganda, advocacy for availability, accessibility and management of Opioid medicines for pain management of terminally ill persons. He has supported a number of African countries to develop guidelines for management of Opioid medicines for palliative Care. He previously served as Board Member of the Palliative Care Association of Uganda. He was Coordinator of GAVI Project in the Ministry of health

for 3 years. Prior to joining the Ministry of Health, he lectured in the department of Pharmacy, Makerere University for over 13 years.

Dr. Sebisubi holds a Post Graduate Diploma in Management from Uganda Management Institute (UMI), a PhD in Pharmaceutical Sciences (collaboratively conducted at Makerere University and the University of Illinois at Chicago), a Master's Degree in Pharmacy and a Bachelor of Science Degree in Chemistry. He was a Post-Doctoral Research Associate for 2 years at the College of Pharmacy, University of Hawaii at Hilo USA.

He has attended a number of meetings and activities in the pharmaceutical sector including palliative care at national, regional and international levels. He has academic papers published in a number of international journals.